Loading...
Home 2018-06-12T13:14:45+00:00

The motivation of our work is…

derived from clinical problems in the treatment of Parkinson’s disease (PD), Amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). Using basic neurobiological techniques, we want to understand the mechanisms of the underlying pathophysiology in degenerative and traumatic CNS disorders. In a translational approach, our group works on the identification of biomarkers and novel therapeutic approaches for neurodegenerative disorders.

Read More >
Principal Investigator
Principal InvestigatorProf. Dr. Paul Lingor

Talks

  • PD Dr. Chi Wang Ip – Universitätsklinikum Würzburg, Germany
    The pathogenic role of the immune system in the AAV1/2-A53T-alpha-synuclein mouse model of Parkinson’s disease.
    Date: Tuesday, 03. July 2018 at 11:00, seminar room
    Location: Center for Biostructural Imaging of Neurodegeneration (BIN)
    Adresse: Von-Siebold-Straße 3a, 37075 Göttingen
    Hosted by: Prof. Dr. Paul Lingor

Selected Original Publications

  • Elemental fingerprint as a cerebrospinal fluid biomarker for the diagnosis of Parkinson’s disease.
    Maass F, Michalke B, Leha A, Börger M, Zerr I, Koch JC, Tönges L, Bähr M, Lingor P.
    J Neurochem 2018 in press. DOI: 10.1111/jnc.14316 PubMed

  • miR-182-5p and miR-183-5p act as GDNF mimics in dopaminergic midbrain neurons.
    Roser AE, Caldi Gomes L, Halder R, Jain G, Maass F, Tönges L, Tatenhorst L, Bähr M, Fischer A, Lingor P.
    Mol Ther Nucl Acids 2018 June (11). https://doi.org/10.1016/j.omtn.2018.01.005